News

Through the collaboration, the companies identified a novel lead series of pan-metallo beta-lactamase inhibitors, which in combination with carbapenems, restores antibacterial activity against life-threatening clinical isolates while exhibiting

According to Bayer, Adempas is currently the only treatment approved for use in two rare types of pulmonary hypertension (PH) – PAH and chronic thromboembolic pulmonary hypertension (CTEPH).

The company has established regional hubs in Singapore and Japan to better enable the industry’s growing need to conduct clinical trials in Asia and/or manage global trials from

Macular Health president and CEO Jeffery McAnnally will announce the new product at the 2014 Optometry’s Marketplace at SECO International in Atlanta, Georgia, on 14 March 2014. McAnnally

An action letter is anticipated before the end of 2014. Carbella is the proposed US trade name for intravenous carbamazepine. Oral carbamazepine is an important treatment option for

The trial met its primary efficacy endpoint of a statistically significant improvement in kidney function. Specifically, a dose of 1.5mg/m2 led to a statistically significant (p=0.045) increase in

Marco Ruo of Marchesini noted worth €1m, the packaging line will demonstrate the hardware and software that is required by pharmaceutical customers to comply with industry regulations for

Temple University is the original owner of the RHB-102 patents. Previously RedHill Biopharma had reported that Scolr Pharma, which originally licensed certain patents to RedHill Biopharma for RHB-102,

The guidance does not include patients with highly active MS. The guidance published by the SMC represents an important step in improving the standard of care available to